Author

Alberto de la Cruz

Institutions: Centro Oncológico de Galicia, GEICAM – Spanish Breast Cancer Group

Observed institutions: Centro Oncológico de Galicia, GEICAM – Spanish Breast Cancer Group

ORCID: 0009-0006-3168-112X

Observed ORCID: 0009-0006-3168-112X

OpenAlex ID: A5148855724

Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial

2026 · Miguel Martín, Alvaro Rodriguez-Lescure, et al. · Clinical Cancer Research · 1

Supplementary Table S1 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial

2026 · Miguel Martín, Alvaro Rodriguez-Lescure, et al.

Supplementary Table S2 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial

2026 · Miguel Martín, Alvaro Rodriguez-Lescure, et al.

Supplementary Figure S1 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial

2026 · Miguel Martín, Alvaro Rodriguez-Lescure, et al.

Supplementary Table S3 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial

2026 · Miguel Martín, Alvaro Rodriguez-Lescure, et al.

Data from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial

2026 · Miguel Martín, Alvaro Rodriguez-Lescure, et al.

Works count: 6

Citation count: 1

H-index: 1

I10-index: